J
J. Carmichael
Researcher at The Royal Marsden NHS Foundation Trust
Publications - 18
Citations - 2188
J. Carmichael is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Olaparib & Cancer. The author has an hindex of 11, co-authored 16 publications receiving 1995 citations. Previous affiliations of J. Carmichael include Institute of Cancer Research.
Papers
More filters
Journal ArticleDOI
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. W. Audeh,J. N. Weitzel,Michael Friedlander,B. K. Arun,Niklas Loman,Rita K. Schmutzler,Andrew M Wardley,Gillian Mitchell,H. M. Earl,Mark Wickens,J. Carmichael +14 more
TL;DR: The results of this study provide positive proof of concept for PARP inhibition in BRCA-deficient breast cancers and shows a favourable therapeutic index for a novel targeted treatment strategy in patients with tumours that have genetic loss of function of BRCa1-associated orBRCA2-associated DNA repair.
Journal ArticleDOI
Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer
Andrew Tutt,Mark E. Robson,Judy Garber,Susan M. Domchek,M. W. Audeh,J. N. Weitzel,M. Friedlander,J. Carmichael +7 more
TL;DR: This first study with olaparib in BRCA-deficient breast cancers provides positive proof of concept for high activity and tolerability of a genetically defined targeted therapy.
Journal ArticleDOI
Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer
M. W. Audeh,Richard T. Penson,Michael Friedlander,B. Powell,Katherine M. Bell-McGuinn,Clare L. Scott,Jeffrey N. Weitzel,J. Carmichael,Andrew Tutt +8 more
TL;DR: Oral olaparib is well tolerated and highly active in advanced, chemotherapy-refractory BRCA-deficient ovarian cancer, with greater activity seen at the higher dose.
Journal ArticleDOI
AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
Peter C.C. Fong,D. S. Boss,Craig P. Carden,M. Roelvink,J. De Greve,Charlie Gourley,J. Carmichael,J.S. de Bono,Jan H.M. Schellens,Stan B. Kaye +9 more
TL;DR: A first-in-human Phase I trial of AZD2281, a novel, potent orally active PARP inhibitor, in BRCA-deficient ovarian cancer, with dose escalation guided by toxicity, pharmacokinetic and pharmacodynamic data, finding that the maximum tolerated dose was 400mg bd.
Journal ArticleDOI
First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (Ku), a small molecule inhibitor of poly ADP-ribose polymerase (PARP) in cancer patients (p), including BRCA1/2 mutation carriers
T. A. Yap,D. S. Boss,Peter C.C. Fong,M. Roelvink,Andrew Tutt,J. Carmichael,Mark J. O'Connor,S. B. Kaye,Jan H.M. Schellens,J.S. de Bono +9 more
TL;DR: Ku is a novel, potent, orally active PARP-1 and 2 inhibitor that induces selective cytotoxicity in cells with defective homologous recombination repair such as BRCA1/2 deficient tumor cells.